Britain’s Health Hypocrisy: When Profit Trumps Public Safety

The Sunbed Scandal: When a Tan Becomes a Death Sentence

The Sunbed Association’s website still claims a tan protects against sunburn. It’s a lie—one that could kill. Leading health organisations, including Cancer Research UK and the British Association of Dermatologists, have spent years debunking this myth. Yet the industry’s trade body persists, peddling dangerous misinformation to a public already confused by mixed messages about skin safety.

Why? Because fear sells. The narrative that a "base tan" offers protection is a marketing goldmine—one that keeps customers coming back, even as melanoma rates climb. The UK already has one of the highest skin cancer rates in Europe, with cases doubling since the 1990s. And while countries like Australia and Brazil have banned commercial sunbeds outright, Britain clings to a flimsy regulatory framework that prioritises industry profits over public health.

The government’s response? A voluntary code of conduct and a warning label that few read. No mandatory age restrictions, no enforceable limits on UV exposure, and no consequences for salons that flout the rules. It’s a system designed to fail—and the bodies piling up in dermatology wards are the proof.

Pharmacies as Prescription Mills: The NHS’s Quiet Privatisation

From this autumn, more pharmacies in England will be able to prescribe medication for five common conditions—ear infections, sore throats, sinusitis, impetigo, and shingles. On paper, it’s a win for accessibility. In practice, it’s a £340m gamble that could turn high-street chemists into little more than pill dispensaries, with all the perverse incentives that entails.

The NHS is already stretched to breaking point. GPs are overworked, waiting times are at record highs, and patients are desperate for alternatives. But handing over prescribing powers to pharmacies—many of which are owned by private equity-backed chains—risks creating a two-tier system: one where those who can afford it see a doctor, and everyone else gets a quick script from a pharmacist with a financial incentive to overprescribe.

Worse, the rollout comes with no clear safeguards. How will pharmacists handle complex cases? What happens when a patient’s symptoms don’t fit the narrow criteria? And who holds these new prescribers accountable when things go wrong? The government’s answer: trust the market. But history shows that when profit enters the equation, patient safety often exits.

HIV Activism’s Lessons: When Care Becomes a Political Act

The Wellcome Collection’s new exhibition, Tenderness and Rage, offers a stark contrast to today’s healthcare failures. In the 1980s and 90s, as HIV ravaged communities, activists didn’t wait for permission to act. They built their own support networks, demanded research funding, and forced governments to confront a crisis they’d rather ignore.

What changed? Not the system—people did. Gay men, women of colour, and refugees turned grief into action, creating spaces where care and protest intertwined. Their legacy is a reminder that healthcare isn’t just about pills and policies; it’s about dignity, solidarity, and the power to fight back.

Britain’s current health scandals—from sunbed lies to pharmacy privatisation—show how far we’ve strayed from that spirit. Today, the fight isn’t just against disease; it’s against a system that treats patients as consumers and safety as an afterthought.

The Pattern No One Wants to See

Three stories, one theme: Britain’s healthcare system is being hollowed out by profit-driven decisions, weak regulation, and political neglect. The sunbed industry sells deadly myths because no one stops them. Pharmacies become prescription mills because the NHS is starved of funding. And HIV activists had to build their own care networks because the state failed them.

The common denominator? A government that talks about "patient choice" while letting corporations dictate the terms. A media that chases scandals but rarely connects the dots. And a public too exhausted to demand better.

The question isn’t whether these failures will cost lives—it’s how many. And whether anyone in power will care enough to stop them.